|
1
|
Harborg S, Kjærgaard KA, Thomsen RW,
Borgquist S, Cronin-Fenton D and Hjorth CF: New horizons:
Epidemiology of obesity, diabetes mellitus, and cancer prognosis. J
Clin Endocrinol Metab. 109:924–935. 2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Varaprasad GL, Gupta VK, Prasad K, Kim E,
Tej MB, Mohanty P, Verma HK, Raju GSR, Bhaskar L and Huh Y: Recent
advances and future perspectives in the therapeutics of prostate
cancer. Exp Hematol Oncol. 12(80)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bergengren O, Pekala KR, Matsoukas K,
Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh
AN, Mucci L, et al: 2022 update on prostate cancer epidemiology and
risk factors-a systematic review. Eur Urol. 84:191–206.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mumuni S, O'Donnell C and Doody O: The
risk factors and screening uptake for prostate cancer: A scoping
review. Healthcare (Basel). 11(2780)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Berenguer CV, Pereira F, Câmara JS and
Pereira JAM: Underlying features of prostate cancer-statistics,
risk factors, and emerging methods for its diagnosis. Curr Oncol.
30:2300–2321. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Babatunde OA, Pearce JL, Jefferson MS,
Frey LJ, Angel PM, Drake RR, Allen CG, Lilly MB, Savage SJ and
Halbert CH: Racial distribution of neighborhood-level social
deprivation in a retrospective cohort of prostate cancer survivors.
Diseases. 10(75)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Abashidze N, Stecher C, Rosenkrantz AB,
Duszak R Jr and Hughes D: Racial and ethnic disparities in the use
of prostate magnetic resonance imaging following an elevated
prostate-specific antigen test. JAMA Netw Open.
4(e2132388)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Aristizabal C, Suther S, Yao Y,
Behar-Horenstein LS, Webb F, Stern MC and Baezconde-Garbanati L:
Training community African American and Hispanic/Latino/a advocates
on prostate cancer (PCa): A multicultural and bicoastal approach. J
Cancer Educ. 38:1719–1727. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Yang J, Xiong X, Zheng W, Liao X, Xu H,
Yang L and Wei Q: Evaluation of survival outcomes among black and
white patients with metastatic castration-resistant prostate
cancer: A systematic review and meta-analysis. Eur Urol Open Sci.
61:10–17. 2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lee KY, Beatson EL, Steinberg SM, Chau CH,
Price DK and Figg WD: Bridging health disparities: A genomics and
transcriptomics analysis by race in prostate cancer. J Racial Ethn
Health Disparities. 11:492–504. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gu J, Chery L, González GMN, Huff C, Strom
S, Jones JA, Griffith DP, Canfield SE, Wang X, Huang X, et al: A
west African ancestry-associated SNP on 8q24 predicts a positive
biopsy in African American men with suspected prostate cancer
following PSA screening. Prostate. 84:694–705. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang A, Shen J, Rodriguez AA, Saunders EJ,
Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, et al:
Characterizing prostate cancer risk through multi-ancestry
genome-wide discovery of 187 novel risk variants. Nat Genet.
55:2065–2074. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Owens OL, Dressler EV, Mayfield A,
Winkfield KM, Krane LS, Foust M and Sandberg JC: Considerations
from employed African-American and white prostate cancer survivors
on prostate cancer treatment and survivorship: A qualitative
analysis. Ethn Health. 29:309–327. 2024.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wu D, Yang Y, Jiang M and Yao R: Competing
risk of the specific mortality among Asian-American patients with
prostate cancer: A surveillance, epidemiology, and end results
analysis. BMC Urol. 22(42)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Würnschimmel C, Wenzel M, Ruvolo CC,
Nocera L, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun
FK, et al: Life expectancy in metastatic prostate cancer patients
according to racial/ethnic groups. Int J Urol. 28:862–869.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Huynh-Le MP, Karunamuni R, Fan CC,
Thompson WK, Muir K, Lophatananon A, Tye K, Wolk A, Håkansson N,
Mills IG, et al: Common genetic and clinical risk factors:
Association with fatal prostate cancer in the Cohort of Swedish
Men. Prostate Cancer Prostatic Dis. 24:845–851. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Abd Ellatif M, Gamal BE, Musaam AO, Malik
A and Tarique M: An update on genetic predisposition for prostate
cancer: Perspectives and prospects. Cell Mol Biol. 69:1–7.
2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Raghallaigh HN and Eeles R: Genetic
predisposition to prostate cancer: An update. Fam Cancer.
21:101–114. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Benafif S, Raghallaigh HN, McHugh J and
Eeles R: Genetics of prostate cancer and its utility in treatment
and screening. Adv Genet. 108:147–199. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Korneenko TV and Pestov NB: Oncogenic
BRCA1,2 mutations in the human lineage-A By-product of sexual
selection? Biomedicines. 12(22)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kalampokis N, Zabaftis C, Spinos T,
Karavitakis M, Leotsakos I, Katafigiotis I, van der Poel H, Grivas
N and Mitropoulos D: Review on the role of BRCA mutations in
genomic screening and risk stratification of prostate cancer. Curr
Oncol. 31:1162–1169. 2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Januskevicius T, Vaicekauskaite I,
Sabaliauskaite R, Matulevicius A, Vezelis A, Ulys A, Jarmalaite S
and Jankevicius F: Germline DNA damage response gene mutations in
localized prostate cancer. Medicina (Kaunas). 60(73)2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Akhoundova D, Francica P, Rottenberg S and
Rubin MA: DNA damage response and mismatch repair gene defects in
advanced and metastatic prostate cancer. Adv Anat Pathol. 31:61–69.
2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Freedland SJ, Samjoo IA, Rosta E, Lansing
A, Worthington E, Niyazov A, Nazari J and Arondekar B: The impact
of race on survival in metastatic prostate cancer: A systematic
literature review. Prostate Cancer Prostatic Dis. 26:461–474.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ledet EM, Burgess EF, Sokolova AO, Jaeger
EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, et
al: Comparison of germline mutations in African American and
Caucasian men with metastatic prostate cancer. Prostate.
81:433–439. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schiff J, Ledet EM, Ernst EM, Garvey CE,
Cotogno P and Sartor O: J Clin Oncol 35: 6 suppl, 2017. https://ascopubs.org/doi/10.1200/JCO.2017.35.6_suppl.225.
|
|
27
|
Zhang W and Zhang K: Quantifying the
contributions of environmental factors to prostate cancer and
detecting risk-related diet metrics and racial disparities. Cancer
Inform. 22(11769351231168006)2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Roach M III, Coleman PW and Kittles R:
Prostate cancer, race, and health disparity. Cancer J. 29:328–337.
2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Epstein M, Syed K, Danella J, Ginzburg S,
Belkoff L, Tomaszewski J, Trabulsi E, Singer EA, Jacobs BL, Raman
JD, et al: Model risk scores may underestimate rate of biochemical
recurrence in African American men with localized prostate cancer:
A cohort analysis of over 3,000 men. Prostate Cancer Prostatic Dis.
27:257–263. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Deuker M, Stolzenbach LF, Pecoraro A,
Rosiello G, Luzzago S, Tian Z, Saad F, Chun FK and Karakiewicz PI:
PSA, stage, grade and prostate cancer specific mortality in Asian
American patients relative to Caucasians according to the United
States Census Bureau race definitions. World J Urol. 39:787–796.
2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hoeh B, Hohenhorst JL, Flammia R,
Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M,
Gallucci M, et al: Cancer-specific mortality after radical
prostatectomy vs external beam radiotherapy in high-risk
Hispanic/Latino prostate cancer patients. Int Urol Nephrol.
54:81–87. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stern N, Ly TL, Welk B, Chin J, Ballucci
D, Haan M and Power N: Association of race and ethnicity with
prostate cancer-specific mortality in Canada. JAMA Netw Open.
4(e2136364)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Whittemore AS, Wu AH, Kolonel LN, John EM,
Gallagher RP, Howe GR, West DW, Teh CZ and Stamey T: Family history
and prostate-cancer risk in black, white, and Asian men in the
United-States and Canada. Am J Epidemiol. 141:732–740.
1995.PubMed/NCBI View Article : Google Scholar
|
|
34
|
El Khoury CJ and Clouston SAP:
Racial/Ethnic disparities in prostate cancer 5-year survival: The
role of health-care access and disease severity. Cancers (Basel).
15(4284)2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yamoah K, Lee KM, Awasthi S, Alba PR,
Perez C, Anglin-Foote TR, Robison B, Gao A, DuVall SL, Katsoulakis
E, et al: Racial and ethnic disparities in prostate cancer outcomes
in the veterans affairs health care system. JAMA Netw Open.
5(e2144027)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Stevens C, Hightower A, Buxbaum SG,
Falzarano SM and Rhie SK: Genomic, epigenomic, and transcriptomic
signatures of prostate cancer between African American and European
American patients. Front Oncol. 13(e2144027)2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Stangl A, Wilner C, Li P, Maahs L, Hwang C
and Pilling A: Molecular features and race-associated outcomes of
mutant metastatic castration-resistant prostate cancer. Prostate.
83:524–533. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kanayama M, Chen Y, Rabizadeh D, Vera L,
Lu C, Nielsen SM, Russell EM, Esplin ED, Wang H, Isaacs WB, et al:
Clinical and functional analyses of an African-ancestry
gain-of-function HOXB13 variant implicated in aggressive prostate
cancer. Eur Urol Oncol. 7:751–759. 2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wei J, Beebe-Dimmer J, Shi Z, Sample C,
Yan G, Rifkin AS, Sadeghpour A, Gielzak M, Choi S, Moon D, et al:
Association of rare, recurrent nonsynonymous variants in the
germline of prostate cancer patients of African ancestry. Prostate.
83:454–461. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Thakker PU, Perry AG, Hemal AK, Bercu CH,
Petrou SP, Pak RW, Broderick GA, Thiel DD, Dora CD, Lyon TD, et al:
Racial, ethnic, and socioeconomic disparities in rates of stage IV
prostate cancer after USPSTF category ‘D’ recommendation against
prostate-specific antigen screening: A retrospective cohort study.
Transl Androl Urol. 13:1093–1103. 2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Ruvolo CC, Würnschimmel C, Nocera L,
Wenzel M, Tian Z, Shariat SF, Saad F, Verze P, Imbimbo C, Briganti
A, et al: Stage and cancer-specific mortality differ within
specific Asian ethnic groups for upper tract urothelial carcinoma:
North American population-based study. Int J Urol. 28:1247–1252.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lim J, Malek R, Jr S, Toh CC, Sundram M,
Woo SYY, Yusoff NAM, Teh GC, Chui BJT, Ng IS, et al: Prostate
cancer in multi-ethnic Asian men: Real-world experience in the
Malaysia prostate cancer (M-CaP) study. Cancer Med. 10:8020–8028.
2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Stopsack KH, Nandakumar S, Arora K, Nguyen
B, Vasselman SE, Nweji B, McBride SM, Morris MJ, Rathkopf DE,
Slovin S, et al: Differences in prostate cancer genomes by
self-reported race: Contributions of genetic ancestry, modifiable
cancer risk factors, and clinical factors. Clin Cancer Res.
28:318–326. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sani MM, Kloping Y and Surahmad F: Benign
prostatic hyperplasia genetic variants in Asians. Clin Chim Acta.
565(119986)2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Graham NJ, Souter LH and Salami SS: A
systematic review of family history, Race/Ethnicity, and genetic
risk on prostate cancer detection and outcomes: Considerations in
PSA-based screening. Urol Oncol. 15:S1078–S1143. 2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chiong E, Murphy DG, Buchan N, Chen K,
Chen SS, Chua MLK, Hamid AR, Kanesvaran R, Khochikar M, Letran J,
et al: Management of advanced prostate cancer in the Asia-Pacific
region: Summary of the Asia-Pacific advanced prostate cancer
consensus conference 2023. Asia Pac J Clin Oncol. 20:481–490.
2024.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liu VN, Van Blarigan EL, Zhang L, Graff
RE, Loeb S, Langlais CS, Cowan JE, Carroll PR, Chan JM and Kenfield
SA: Plant-based diets and disease progression in men with prostate
cancer. JAMA Netw Open. 7(e249053)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mitchell E, Comerford K, Knight M,
McKinney K and Lawson Y: A review of dairy food intake for
improving health among black adults in the US. J Natl Med Assoc.
116:253–273. 2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kimura T and Egawa S: Epidemiology of
prostate cancer in Asian countries. Int J Urol. 25:524–531.
2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ge S, Zha L, Sobue T, Kitamura T, Ishihara
J, Iwasaki M, Inoue M, Yamaji T, Tsugane S and Sawada N: Dietary
consumption of antioxidant vitamins in relation to prostate cancer
risk in Japanese men: The Japan public health center-based
prospective study. J Epidemiol. 34:144–153. 2024.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Krishnan S, Kanthaje S, Punchappady DR,
Mujeeburahiman M and Ratnacaram CK: Circulating metabolite
biomarkers: A game changer in the human prostate cancer diagnosis.
J Cancer Res Clin Oncol. 149:951–967. 2023.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ko YH and Kim BH: Should contemporary
western guidelines based on studies conducted in the 2000s be
adopted for the prostate-specific antigen screening policy for
Asian men in the 2020s? World J Mens Health. 40:1–8.
2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang CM, Yuan L, Liu XH, Chen SQ, Wang HF,
Dong QF, Zhang B, Huang MS, Zhang ZY, Xiao J and Tao T: Developing
a diagnostic model for predicting prostate cancer: A retrospective
study based on Chinese multicenter clinical data. Asian J Androl.
26:34–40. 2024.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Pandit AA, Halpern MT, Gressler LE, Kamel
M, Payakachat N and Li C: Association of race/ethnicity and patient
care experiences with receipt of definitive treatment among
prostate cancer survivors: A SEER-CAHPS study. Cancer Causes
Control. 35:647–659. 2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Alkhatib KY, Filipas DK, Briggs L, Frego
N, Koelker M, Lipsitz SR, Pierorazio PM, Rebbeck T, Kilbridge K,
Kibel AS, et al: Racial differences in knowledge, attitudes, and
sources of information about germline cancer genetic testing in the
USA: An analysis of the health information national trends survey
system. Prev Med. 178(107779)2024.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Sweis J, Ofori B and Murphy AB: Concerns
regarding prostate cancer screening guidelines in minority
populations. Prostate Cancer Prostatic Dis. 27:591–593.
2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Sasaki T, Matsumoto R, Higashi S, Kato M,
Masui S, Yoshio Y, Nishikawa K and Inoue T: Impact of family
history on clinicopathological variables and disease progression in
Japanese prostate cancer patients undergoing robotic-assisted
radical prostatectomy. Int J Urol. 29:1339–1346. 2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Xu J, Resurreccion WK, Shi Z, Wei J, Wang
CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand B, et al:
Inherited risk assessment and its clinical utility for predicting
prostate cancer from diagnostic prostate biopsies. Prostate Cancer
Prostatic Dis. 25:422–430. 2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Giri VN, Morgan TM, Morris DS, Berchuck
JE, Hyatt C and Taplin ME: Genetic testing in prostate cancer
management: Considerations informing primary care. CA Cancer J
Clin. 72:360–371. 2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Cui H, Zhang W, Zhang L, Qu Y, Xu Z, Tan
Z, Yan P, Tang M, Yang C, Wang , et al: Risk factors for
prostate cancer: An umbrella review of prospective observational
studies and mendelian randomization analyses. PLoS Med.
21(e1004362)2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Seibert TM, Garraway IP, Plym A, Mahal BA,
Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA and
Morgan TM: Genetic risk prediction for prostate cancer:
Implications for early detection and prevention. Eur Urol.
83:241–248. 2023.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Takeuchi T, Hattori-Kato M, Okuno Y,
Nomiya A, Fukuhara H, Zaitsu M and Azuma T: A genome-wide
association study of prostate cancer susceptibility using
occupational and environmental factors as confounding factors.
Cureus. 16(e52926)2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Farashi S, Kryza T, Clements J and Batra
J: Post-GWAS in prostate cancer: From genetic association to
biological contribution. Nat Rev Cancer. 19:46–59. 2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Teerlink CC, Leongamornlert D, Dadaev T,
Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid
DJ, Catalona WJ, et al: Genome-wide association of familial
prostate cancer cases identifies evidence for a rare segregating
haplotype at 8q24.21. Hum Genet. 135:923–938. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Benafif S and Eeles R: Genetic
predisposition to prostate cancer. Br Med Bull. 120:75–89.
2016.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Hall R, Bancroft E, Pashayan N, Kote-Jarai
Z and Eeles RA: Genetics of prostate cancer: A review of latest
evidence. J Med Genet. 61:915–926. 2024.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Bıyıkoğlu M, Tanrıverdi R, Bozlu M, Şenel
S, Fidancı ŞB, Tamer L and Akbay E: Evaluation of homeobox protein
B13 (HOXB13) gene G84E mutation in patients with prostate cancer.
World J Urol. 42(476)2024.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Heise M, Jarzemski P, Nowak D, Bąk A,
Junkiert-Czarnecka A, Pilarska-Deltow M, Borysiak M, Pilarska B and
Haus O: Clinical significance of gene mutations and polymorphic
variants and their association with prostate cancer risk in Polish
men. Cancer Control. 29(10732748211062342)2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Nyberg T, Brook MN, Ficorella L, Lee A,
Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, et al:
CanRisk-Prostate: A comprehensive, externally validated risk model
for the prediction of future prostate cancer. J Clin Oncol.
41:1092–1104. 2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Dairo O, DePaula Oliveira L, Schaffer E,
Vidotto T, Mendes AA, Lu J, Huynh SV, Hicks J, Sowalsky AG, De
Marzo AM, et al: Gene methylation is associated with fatty acid
synthase expression and clinical-genomic features of prostate
cancer. Cancer Res Commun. 4:152–163. 2024.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Panebianco M, Cereda V and D'Andrea MR:
Combination of the PARPi and ARSi in advanced castration resistant
prostate cancer: A review of the recent phase III trials. Explor
Target Antitumor Ther. 5:997–1010. 2024.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Zhao D, Wang A, Li Y, Cai X, Zhao J, Zhang
T, Zhao Y, Dong Y, Zhou F, Li Y and Wang J: Establishing the
homologous recombination score threshold in metastatic prostate
cancer patients to predict the efficacy of PARP inhibitors. J Natl
Cancer Cent. 4:280–287. 2024.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Castro E: PARP inhibitor addition to
androgen receptor pathway inhibitors in metastatic
castration-resistant prostate cancer should be limited to BRCA
mutation carriers. Eur Urol Focus. 10:504–505. 2024.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Hassanin E, May P, Aldisi R, Spier I,
Forstner AJ, Nöthen MM, Aretz S, Krawitz P, Bobbili DR and Maj C:
Breast and prostate cancer risk: The interplay of polygenic risk,
rare pathogenic germline variants, and family history. Genet Med.
24:576–585. 2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Oliynyk RT: Evaluating the potential of
younger cases and older controls cohorts to improve discovery power
in genome-wide association studies of late-onset diseases. J Pers
Med. 9(38)2019.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Graff RE, Möller S, Passarelli MN, Witte
JS, Skytthe A, Christensen K, Tan Q, Adami HO, Czene K, Harris JR,
et al: Familial risk and heritability of colorectal cancer in the
nordic twin study of cancer. Clin Gastroenterol Hepatol.
15:1256–1264. 2017.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Ponti G, De Angelis C, Ponti R, Pongetti
L, Losi L, Sticchi A, Tomasi A and Ozben T: Hereditary breast and
ovarian cancer: From genes to molecular targeted therapies. Crit
Rev Clin Lab Sci. 60:640–650. 2023.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Abdel-Razeq H, Sharaf B, Tamimi F, Hani
HB, Alsmadi O, Khalil H, Abunasser M, Edaily S and Mansour A:
Establishment of a clinical cancer genetics program for breast
cancer in a resource-limited country; challenges and opportunities.
Front Oncol. 14(1431985)2024.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Allen I, Hassan H, Walburga Y, Huntley C,
Loong L, Rahman T, Allen S, Garrett A, Torr B, Bacon A, et al:
Second primary cancer risks after breast cancer in BRCA1 and BRCA2
pathogenic variant carriers. J Clin Oncol.
29(JCO2401146)2024.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Fanale D, Corsini LR, Brando C, Randazzo
U, Bono M, Pedone E, Perez A, Sciacchitano R, Cancelliere D,
Piraino P, et al: BRCA-associated hereditary male cancers: Can
gender affect the prevalence and spectrum of germline pathogenic
variants? Front Oncol. 14(1414343)2024.PubMed/NCBI View Article : Google Scholar
|
|
81
|
John AO, Singh A, Yadav P, Joel A, Thumaty
DB, Ninan KF, Georgy JT, Cherian AJ, Thomas S, Thomas A, et al: The
BRCA mutation spectrum among breast and ovarian cancers in India:
Highlighting the need to screen BRCA1 185delAG among South Indians.
Eur J Hum Genet. 32:1319–1326. 2024.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Marino F, Totaro A, Gandi C, Bientinesi R,
Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P and Sacco E:
Germline mutations in prostate cancer: A systematic review of the
evidence for personalized medicine. Prostate Cancer Prostatic Dis.
26:655–664. 2023.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Lukashchuk N, Barnicle A, Adelman CA,
Armenia J, Kang J, Barrett JC and Harrington EA: Impact of DNA
damage repair alterations on prostate cancer progression and
metastasis. Front Oncol. 13(1162644)2023.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Bugoye FC, Torrorey-Sawe R, Biegon R,
Dharsee N, Mafumiko FMS, Patel K and Mining SK: Mutational spectrum
of DNA damage and mismatch repair genes in prostate cancer. Front
Genet. 14(1231536)2023.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z,
Zhang X, Ren X, Wang S and Qin C: Prognostic role of DNA damage
response genes mutations and their association with the sensitivity
of olaparib in prostate cancer patients. Cancer Control.
29(10732748221129451)2022.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Reiter K and Hassler MR: Genetic testing
and management of prostate cancer patients with pathogenic germline
variants. Memo-Magazine of European Medical Oncology. 17:51–56.
2024.
|
|
87
|
Steinkellner L, Luger F and Loidl W:
Importance of genetic testing in prostate cancer. Urologie.
61:1392–1396. 2022.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
88
|
Rajwa P, Quhal F, Pradere B, Gandaglia G,
Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger
AS, et al: Prostate cancer risk, screening and management in
patients with germline mutations. Nat Rev Urol. 20:205–216.
2023.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Inoue T, Sekito S, Kageyama T, Sugino Y
and Sasaki T: Roles of the PARP inhibitor in BRCA1 and BRCA2
pathogenic mutated metastatic prostate cancer: Direct functions and
modification of the tumor microenvironment. Cancers (Basel).
15(2662)2023.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Chen JY, Wang PY, Liu MZ, Lyu F, Ma MW,
Ren XY and Gao XS: Biomarkers for prostate cancer: From diagnosis
to treatment. Diagnostics (Basel). 13(3350)2023.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Petrucelli N, Daly MB and Pal T: BRCA1-
and BRCA2-associated hereditary breast and ovarian cancer, In
GeneReviews((R)), M.P. Adam et al., Editors. 1993: Seattle
(WA).
|
|
92
|
Ragupathi A, Singh M, Perez AM and Zhang
D: Targeting the BRCA1/2 deficient cancer with PARP inhibitors:
Clinical outcomes and mechanistic insights. Front Cell Dev Biol.
11(1133472)2023.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Bychkovsky BL, Li T, Sotelo J, Tayob N,
Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, et
al: Identification and management of pathogenic variants in BRCA1,
BRCA2, and PALB2 in a tumor-only genomic testing program. Clin
Cancer Res. 28:2349–2360. 2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Nukaya T, Sumitomo M, Sugihara E, Takeda
M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K,
Shiroki R and Saya H: Estimating copy number to determine BRCA2
deletion status and to expect prognosis in localized prostate
cancer. Cancer Med. 12:8154–8165. 2023.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Foley GR, Marthick JR, Ostrander EA,
Stanford JL, Dickinson JL and FitzGerald LM: Association of a novel
BRCA2 mutation with prostate cancer risk further supports germline
genetic testing. Eur J Cancer. 180:155–157. 2023.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Nyberg T, Tischkowitz M and Antoniou AC:
BRCA1 and BRCA2 pathogenic variants and prostate cancer risk:
Systematic review and meta-analysis. Br J Cancer. 126:1067–1081.
2022.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Xie C, Luo J, He Y, Jiang L, Zhong L and
Shi Y: BRCA2 gene mutation in cancer. Medicine (Baltimore).
101(e31705)2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Hongo H, Kosaka T, Hayashi H, Nakamura K,
Nishihara H, Mikami S, Beltran H and Oya M: Germline BRCA2 mutation
in a case of aggressive prostate cancer accompanied by spinal
bulbar muscular atrophy. Asian J Androl. 24:116–118.
2022.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Thorne H, Devereux L, Li J, Alsop K,
Christie L, van Geelen CT, Burdett N, Pishas KI, Woodford N,
Leditschke J, et al: BRCA1 and BRCA2 carriers with breast, ovarian
and prostate cancer demonstrate a different pattern of metastatic
disease compared with non-carriers: Results from a rapid autopsy
programme. Histopathology. 83:91–103. 2023.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Paulo P, Cardoso M, Brandão A, Pinto P,
Falconi A, Pinheiro M, Cerveira N, Silva R, Santos C, Pinto C, et
al: Genetic landscape of homologous recombination repair genes in
early-onset/familial prostate cancer patients. Genes Chromosomes
Cancer. 62:710–720. 2023.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL
and Ma ESK: Molecular characteristics of Asian male-related
cancers. Breast Cancer Res Treat. 198:391–400. 2023.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Fettke H, Dai C, Kwan EM, Zheng T, Du P,
Ng N, Bukczynska P, Docanto M, Kostos L, Foroughi S, et al:
BRCA-deficient metastatic prostate cancer has an adverse prognosis
and distinct genomic phenotype. EbioMedicine.
95(104738)2023.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Barnes DR, Silvestri V, Leslie G, McGuffog
L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K,
et al: Breast and prostate cancer risks for male BRCA1 and BRCA2
pathogenic variant carriers using polygenic risk scores. J Natl
Cancer Inst. 114:109–122. 2022.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Marchetti C, Ataseven B, Cassani C, Sassu
CM, Congedo L, D'Indinosante M, Cappuccio S, Rhiem K, Hahnen E,
Cordisco EL, et al: Ovarian cancer onset across different mutation
types: A view to a more tailored approach for BRCA mutated
patients. Int J Gynecol Cancer. 33:257–262. 2023.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Osman K, Ahmet K, Hilmi T, İlker NO, Ercan
Ö, Devrim Ç, Murat S, Emre Ç, İlhan H, Mustafa G, et al: BRCA
1/BRCA 2 pathogenic/likely pathogenic variant patients with breast,
ovarian, and other cancers. Balkan J Med Genet. 25:5–14.
2022.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Mitsueda R, Toda H, Shinden Y, Fukuda K,
Yasudome R, Kato M, Kikkawa N, Ohtsuka T, Nakajo A and Seki N:
Oncogenic targets regulated by tumor-suppressive miR-30c-1-3p and
miR-30c-2-3p: TRIP13 facilitates cancer cell aggressiveness in
breast cancer. Cancers (Basel). 15(4189)2023.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Loboda AP, Adonin LS, Zvereva SD, Guschin
DY, Korneenko TV, Telegina AV, Kondratieva OK, Frolova SE, Pestov
NB and Barlev NA: BRCA mutations-the achilles heel of breast,
ovarian and other epithelial cancers. Int J Mol Sci.
24(4982)2023.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Lavoro A, Scalisi A, Candido S, Zanghì GN,
Rizzo R, Gattuso G, Caruso G, Libra M and Falzone L: Identification
of the most common BRCA alterations through analysis of germline
mutation databases: Is droplet digital PCR an additional strategy
for the assessment of such alterations in breast and ovarian cancer
families? Int J Oncol. 60(58)2022.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Werner H: BRCA1: An endocrine and
metabolic regulator. Front Endocrinol (Lausanne).
13(844575)2022.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Russi M, Marson D, Fermeglia A, Aulic S,
Fermeglia M, Laurini E and Pricl S: The fellowship of the RING:
BRCA1, its partner BARD1 and their liaison in DNA repair and
cancer. Pharmacol Ther. 232(108009)2022.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Lee CL, Holter S, Borgida A, Dodd A,
Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, et al:
Germline BRCA2 variants in advanced pancreatic acinar cell
carcinoma: A case report and review of literature. World J
Gastroenterol. 28:6421–6432. 2022.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Boussios S, Rassy E, Moschetta M, Ghose A,
Adeleke S, Sanchez E, Sheriff M, Chargari C and Pavlidis N: BRCA
mutations in ovarian and prostate cancer: Bench to bedside. Cancers
(Basel). 14(3888)2022.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Werner H and Laron Z: Role of the GH-IGF1
system in progression of cancer. Mol Cell Endocrinol.
518(111003)2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Sharon SM, Pozniak Y, Geiger T and Werner
H: TMPRSS2-ERG fusion protein regulates insulin-like growth
factor-1 receptor (IGF1R) gene expression in prostate cancer:
Involvement of transcription factor Sp1. Oncotarget. 7:51375–51392.
2016.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Alanee SR, Glogowski EA, Schrader KA,
Eastham JA and Offit K: Clinical features and management of BRCA1
and BRCA2-associated prostate cancer. Front Biosci (Elite Ed).
6:15–30. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
116
|
Moro L, Arbini AA, Yao JL, di Sant'Agnese
PA, Marra E and Greco M: Loss of BRCA2 promotes prostate cancer
cell invasion through up-regulation of matrix metalloproteinase-9.
Cancer Sci. 99:553–563. 2008.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Rein HL and Bernstein KA: Finding
significance: New perspectives in variant classification of the
RAD51 regulators, BRCA2 and beyond. DNA Repair (Amst).
130(103563)2023.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Edwards SM, Evans DG, Hope Q, Norman AR,
Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P,
et al: Prostate cancer in germline mutation carriers is associated
with poorer prognosis. Br J Cancer. 103:918–924. 2010.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi
R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, et
al: Two percent of men with early-onset prostate cancer harbor
germline mutations in the gene. Am J Hum Genet. 72:1–12.
2003.PubMed/NCBI View
Article : Google Scholar
|
|
120
|
Gallagher DJ, Cronin AM, Milowsky MI,
Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K and Robson
ME: Germline mutation does not prevent response to taxane-based
therapy for the treatment of castration-resistant prostate cancer.
BJU Int. 109:713–719. 2012.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Gallagher DJ, Vijai J, Cronin AM, Bhatia
J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, et
al: Susceptibility loci associated with prostate cancer progression
and mortality. Clin Cancer Res. 16:2819–2832. 2010.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Thorne H, Willems AJ, Niedermayr E, Hoh
IM, Li J, Clouston D, Mitchell G, Fox S and Hopper JL: Kathleen
Cunningham Consortium for Research in Familial Breast Cancer
Consortium. Bolton D: Decreased prostate cancer-specific survival
of men with mutations from multiple breast cancer families. Cancer
Prev Res (Phila). 4:1002–1010. 2011.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Tryggvadóttir L, Vidarsdóttir L,
Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar
T, Thorlacius S, Jonsson E, Eyfjord JE and Tulinius H: Prostate
cancer progression and survival in BRCA2 mutation carriers. J Natl
Cancer Inst. 99:929–935. 2007.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Narod SA, Neuhausen S, Vichodez G, Armel
S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D,
Couch F, et al: Rapid progression of prostate cancer in men with a
mutation. Br J Cancer. 99:371–374. 2008.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Castro E, Jugurnauth-Little S, Karlsson Q,
Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D,
Dadaev T, Govindasami K, Guy M, et al: High burden of copy number
alterations and c-MYC amplification in prostate cancer from BRCA2
germline mutation carriers. Ann Oncol. 26:2293–2300.
2015.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Castro E, Salles DC, Lozano R, Thorne H,
Aragon I, Campos FL, Rubio J, Pecharroman AG, Prieto D, Lozano IG,
et al: Association between BRCA2 status and histologic variants
(intraductal (IDC) and cribriform (CRIB) histology) in prostate
cancer (PC). J Clin Oncol. 38:74–83. 2020.
|
|
127
|
Castro E, Goh C, Olmos D, Saunders E,
Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami
K, Guy M, et al: Germline BRCA mutations are associated with higher
risk of nodal involvement, distant metastasis, and poor survival
outcomes in prostate cancer. J Clin Oncol. 31:1748–1757.
2013.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Shee K, Cowan JE, Balakrishnan A, Escobar
D, Chang K, Washington SL III, Nguyen HG, Shinohara K, Cooperberg
MR and Carroll PR: Limited relevance of the very low risk prostate
cancer classification in the modern era: Results from a large
institutional active surveillance cohort. Eur Urol. 84:9–12.
2023.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Xie M, Gao XS, Ma MW, Gu XB, Li HZ, Lyu F,
Bai Y, Chen JY, Ren XY and Liu MZ: Population-based comparison of
different risk stratification systems among prostate cancer
patients. Front Oncol. 11(646073)2021.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Ellis SD, Blackard B, Carpenter WR, Mishel
M, Chen RC, Godley PA, Mohler JL and Bensen JT: Receipt of national
comprehensive cancer network guideline-concordant prostate cancer
care among African American and Caucasian American men in North
Carolina. Cancer. 119:2282–2290. 2013.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Ueki A, Yoshida R, Kosaka T and
Matsubayashi H: Clinical risk management of breast, ovarian,
pancreatic, and prostatic cancers for variant carriers in Japan. J
Hum Genet. 68:517–526. 2023.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Militaru FC, Militaru V, Crisan N, Bocsan
IC, Udrea AA, Catana A, Kutasi E and Militaru MS: Molecular basis
and therapeutic targets in prostate cancer: A comprehensive review.
Biomol Biomed. 23:760–771. 2023.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Margel D, Benjaminov O, Ozalvo R, Grievink
LS, Kedar I, Yerushalmi R, Ben-Aharon I, Neiman V, Yossepowitch O,
Kedar D, et al: Personalized prostate cancer screening among men
with high risk genetic predisposition- study protocol for a
prospective cohort study. BMC Cancer. 14(528)2014.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Wan A, Zhang G, Ma D, Zhang Y and Qi X: An
overview of the research progress of BRCA gene mutations in breast
cancer. Biochim Biophys Acta Rev Cancer.
1878(188907)2023.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Slootbeek PHJ, Overbeek JK, Ligtenberg
MJL, van Erp NP and Mehra N: PARPing up the right tree; an overview
of PARP inhibitors for metastatic castration-resistant prostate
cancer. Cancer Lett. 577(216367)2023.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Xu J, Ma C, Hirschey R, Liu J, Neidre DB,
Nielsen ME, Keyserling TC, Tan X and Song L: Associations of role,
area deprivation index, and race with health behaviors and body
mass index among localized prostate cancer patients and their
partners. J Cancer Surviv.
18(10.1007/s11764-024-01625-z)2024.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Trendowski MR, Ruterbusch JJ, Baird TE,
Wenzlaff AS, Pandolfi SS, Hastert TA, Schwartz AG and Beebe-Dimmer
JL: Correlates of health-related quality of life in African
Americans diagnosed with cancer: A review of survivorship studies
and the Detroit research on cancer survivors cohort. Cancer
Metastasis Rev. 43:1373–1384. 2024.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Delgado D, Gillard M, Tong L, Demanelis K,
Oliva M, Gleason KJ, Chernoff M, Chen L, Paner GP, Griend DV and
Pierce BL: The impact of inherited genetic variation on DNA
methylation in prostate cancer and benign tissues of African
American and European American Men. Cancer Epidemiol Biomarkers
Prev. 33:557–566. 2024.PubMed/NCBI View Article : Google Scholar
|
|
139
|
Tipre M, Hardy C, Bowman T, Glover M,
Gullet P, Baity D, Levy K and Baskin ML: Concept mapping with black
men: Barriers to prostate cancer screening and solutions. J Cancer
Educ. 38:1808–1815. 2023.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Wang EY, Borno HT, Washington Iii SL,
Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM,
Shariff-Marco S, Beatty AL and Kenfield S: Engaging men of diverse
racial and ethnic groups with advanced prostate cancer in the
design of an mHealth diet and exercise intervention: Focus group
study. JMIR Cancer. 9(e45432)2023.PubMed/NCBI View
Article : Google Scholar
|
|
141
|
Lei F and Lee E: Cancer screening rates
among Asian Americans: A cross-sectional secondary data analysis
study. Cancer Control. 30(10732748231202462)2023.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Wadhwa A, Han K, Ramirez-Velandia F,
Alwakaa O, Riordan C, McNeil E, Granstein JH, Taussky P,
Enriquez-Marulanda A, Ogilvy CS, et al: Neighborhood deprivation,
race and ethnicity, and prostate cancer outcomes across California
health care systems. JAMA Netw Open. 7(e242852)2024.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Frego N, Beatrici E, Labban M, Stone BV,
Filipas DK, Koelker M, Lughezzani G, Buffi NM, Osman NY, Lipsitz
SR, et al: Racial disparities in prostate cancer screening: The
role of shared decision making. Am J Prev Med. 66:27–36.
2024.PubMed/NCBI View Article : Google Scholar
|
